anlotinib

Key facts

Mechanism of action

Platelet-derived growth factor receptor beta inhibitor

Primary target: Platelet-derived growth factor receptor beta

Approval history

1. 2025-SR-813 Phase 2 · First People's Hospital · Esophageal Cancer
2. AK105 and anlotinib Phase 2 · First People's Hospital · Cervical Cancer
3. Anlotinib Phase 2 · First People's Hospital · Non-Small-Cell Lung Cancer
4. Anlotinib Hydrochloride Phase 2 · First People's Hospital · Effect of Drugs
5. Anlotinib and Sintilimab injection Phase 2 · First People's Hospital · Advanced Hepatocellular Carcinoma
6. Anlotinib combined Docetaxel Phase 2 · Chinese Academy of · Non-small Cell Lung Cancer
7. Anlotinib plus Pemetrexed Phase 2 · Henan Provincial People's · Non-squamous Cell Non-Small Cell Lung Cancer
8. Anlotinib+ Liposomal Doxorubicin Phase 2 · First People's Hospital · Sarcoma

1. sorafenib tosylate Vascular endothelial growth factor receptor inhibitor
2. tivozanib hydrochloride Vascular endothelial growth factor receptor inhibitor
3. tivozanib hydrochloride monohydrate Antineoplastic and immunomodulating agents (L01)

Frequently asked questions